Compare Tractor Supply Co (TSCO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tractor Supply Co vs Viatris Inc — how do they compare? Tractor Supply Co trades at $33.24 (market cap $17.44B), while Viatris Inc trades at $17.35 (market cap $20.03B). The key difference: Tractor Supply Co and Viatris Inc are close in size by market cap, and Tractor Supply Co pays the higher dividend (2.87%). Which is the better fit depends on your goals — on Pluang, investors hold Tractor Supply Co for 88 Days and Viatris Inc for 57 Days on average.
| TSCO | VTRS | |
|---|---|---|
Market Cap | $17.44B | $20.03B |
Volume | 10,598,723 | 14,109,977 |
Sector | Consumer Cyclical | Health |
52-Week High | $56.37 | $18.27 |
52-Week Low | $29.14 | $9.74 |
Typical Hold Time | 88 Days | 57 Days |
Enterprise Value | $23.76B | $32.15B |
Dividend Yield | 2.87% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tractor Supply (TSCO) trades at $32.52, up 0.71% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported revenue of $15.52B in 2025, with a net income margin of 6.42% and a P/E ratio of 17.44. Recent earnings misses and a dividend streak under scrutiny are balanced by expansion efforts, including a new distribution center in Idaho.
The outlook is mixed; analyst consensus is a $36.76 price target with a near-even split between buy and hold ratings. Risks include consecutive earnings misses and competitive pressures, but the company's strong ROE of 39.51% and consistent dividend history offer potential for patient investors amid cyclical challenges.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tractor Supply Co
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,016 of its namesake banners in 49 states and 178 Petsense stores. Stores are typically located in towns outside of urban areas and in rural communities. In fiscal 2021, revenue consisted primarily of livestock and pet (47%), hardware, tools, and truck (21%), and seasonal gift and toy (21%).
Read more on TSCO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
